Using the Angiogenesis Inhibitor Pazopanib to Treat Ovarian Cancer
June 2nd 2013Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses a phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.